DM ( DrugBank: - )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	3
8	Huntington disease	1

6. Parkinson disease

---

Clinical trials : 2,307 /  Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2000039475	2020-11-01	2020-10-29	Cardiac structural and functional study in Parkinson's Disease with Cardiac Autonomic Neuropathy	Cardiac structural and functional study in Parkinson's Disease with Cardiac Autonomic Neuropathy	Parkinson's Disease	PD Group:not available;MSA Group:not available;DM Group:not available;HC Group :not available ;	Guangdong Provincial People's Hospital	NULL	Recruiting	50	80	Both	PD Group:80;MSA Group:20;DM Group:20;HC Group :40;		China
2	NCT01515410 (ClinicalTrials.gov)	January 2012	11/1/2012	Study in Advanced Parkinson's Disease Patients With Predictable Motor Fluctuations	A Phase 2, Randomized, Open-Label, Crossover Study to Compare DM-1992, a Novel Gastric-Retentive Extended-Release Formulation of Levodopa/Carbidopa, to an Immediate-Release Carbidopa Tablet in Patients With Advanced Parkinson's Disease With Motor Fluctuations	Parkinson's Disease;Motor Fluctuations	Drug: DM-1992;Drug: Sinemet IR	Depomed	NULL	Completed	30 Years	N/A	All	34	Phase 2	United States
3	EUCTR2010-019396-29-IT (EUCTR)	18/05/2010	05/03/2012	Levodopa and Pramipexole dministration modalities in patients affected by parkinson desease.	Levodopa Administration Modalities and Pramipexole in Parkinson's Disease (LAMP-PD study) A multicenter, randomized, four parallel groups, active-controlled, open-label study to evaluate the risk of dyskinesia in early PD. - LAMP-PD	Patients with idiopathic Parkinson's Disease.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	INN or Proposed INN: Levodopa and decarboxylase inhibitor Trade Name: COMTAN INN or Proposed INN: Entacapone INN or Proposed INN: Levodopa and decarboxylase inhibitor Trade Name: STALEVO*100CPR 50/12,5/200MG INN or Proposed INN: Levodopa, decarboxylase inhibitor and COMT inhibitor Trade Name: STALEVO*100CPR 100/25/200MG INN or Proposed INN: Levodopa, decarboxylase inhibitor and COMT inhibitor INN or Proposed INN: Levodopa and decarboxylase inhibitor INN or Proposed INN: Levodopa and decarboxylase inhibitor INN or Proposed INN: Levodopa and decarboxylase inhibitor INN or Proposed INN: Levodopa and decarboxylase inhibitor INN or Proposed INN: Levodopa and decarboxylase inhibitor INN or Proposed INN: Levodopa and decarboxylase inhibitor INN or Proposed INN: Levodopa and decarboxylase inhibitor INN or Proposed INN: Levodopa and decarboxylase inhibitor	AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO-VITTORIO EMANUELE	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy

8. Huntington disease

---

Clinical trials : 242 /  Drugs : 205 - (DrugBank : 62) / Drug target genes : 85 - Drug target pathways : 159

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03854019 (ClinicalTrials.gov)	August 5, 2019	22/2/2019	Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease	Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease	Huntington Disease;Irritability	Drug: Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg);Drug: Placebo	The University of Texas Health Science Center, Houston	Cures Within Reach	Recruiting	18 Years	75 Years	All	22	Phase 3	United States